Pharos iBio Co., Ltd. (KOSDAQ:388870)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,840.00
+870.00 (14.57%)
At close: Nov 19, 2025
14.57%
Market Cap88.55B
Revenue (ttm)n/a
Net Income (ttm)-9.82B
Shares Out12.95M
EPS (ttm)-759.21
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,202,608
Average Volume1,043,939
Open6,100.00
Previous Close5,970.00
Day's Range6,030.00 - 7,760.00
52-Week Range4,630.00 - 9,740.00
Beta0.22
RSI61.52
Earnings DateNov 14, 2025

About Pharos iBio

Pharos iBio Co., Ltd. develops treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer; PHI-101-TNBC for the treatment of metastatic triple-negative breast cancer; PHI-101-RS, a radiation sensitizer; PHI-201, a K-Ras hub-protein inhibitor; PHI-301, a FAK hub-p... [Read more]

Industry Pharmaceutical Preparations
Founded 2016
Employees 33
Stock Exchange KOSDAQ
Ticker Symbol 388870
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.